| Market Cap | 22.59M | P/E | - | EPS this Y | -11.00% | Ern Qtrly Grth | - |
| Income | -49.25M | Forward P/E | -0.52 | EPS next Y | 27.10% | 50D Avg Chg | -10.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 148.00% |
| Dividend | N/A | Price/Book | 0.85 | EPS next 5Y | - | 52W High Chg | -46.00% |
| Recommedations | 1.80 | Quick Ratio | 1.43 | Shares Outstanding | 7.82M | 52W Low Chg | 889.00% |
| Insider Own | 2.67% | ROA | -81.22% | Shares Float | 6.73M | Beta | 1.50 |
| Inst Own | 27.63% | ROE | -180.44% | Shares Shorted/Prior | 30.47K/30.43K | Price | 3.56 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 157,688 | Target Price | 15.83 |
| Oper. Margin | - | Earnings Date | Nov 9 | Volume | 66,617 | Change | 8.21% |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
| Piper Sandler | Overweight | Aug 11, 23 |
| RBC Capital | Outperform | Aug 11, 23 |
| HC Wainwright & Co. | Buy | Aug 11, 23 |
| Oppenheimer | Outperform | Aug 11, 23 |
| Cantor Fitzgerald | Overweight | Jun 12, 23 |
| HC Wainwright & Co. | Buy | Jun 12, 23 |
| Oppenheimer | Outperform | Jun 12, 23 |
| Piper Sandler | Overweight | Jun 7, 23 |
| RBC Capital | Outperform | Jun 7, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Seizinger Bernd R. | Director Director | Sep 22 | Buy | 3.14 | 17,000 | 53,380 | 17,000 | 09/25/23 |
| Payne Fletcher | SR VP & Chief Fin. O.. SR VP & Chief Fin. Officer | Sep 19 | Buy | 0.6775 | 10,000 | 6,775 | 10,000 | 09/21/22 |
| - | - - | Aug 05 | Buy | 2.65 | 57,199 | 151,577 | 8,948,275 | 08/05/21 |
| - | - - | Aug 05 | Sell | 2.62 | 60,000 | 157,200 | 8,888,275 | 08/05/21 |
| Whitehead Warren | Director Director | Dec 28 | Option | 2.01 | 20,000 | 40,200 | 60,000 | 12/28/20 |
| Whitehead Warren | Director Director | Dec 28 | Sell | 4.06 | 20,000 | 81,200 | 40,000 | 12/28/20 |